Results 231 to 240 of about 383,545 (307)

Contraindicated drug–drug interactions and associated adverse drug reactions in an observational cohort study of 4543 paediatric hospitalized patients

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval, Sylvain Goutelle, Inesse Boussaha, Xavier Dode, Yanis Mimouni, Kim An Nguyen, Behrouz Kassai   +6 more
wiley   +1 more source

Adult Leigh Syndrome Associated with the m.15635T>C Mitochondrial DNA Variant Affecting the Cytochrome <i>b</i> (<i>MT-CYB</i>) Gene. [PDF]

Int J Mol Sci
Tropeano CV, La Morgia C, Achilli A, Iommarini L, Tioli G, Caporali L, Olivieri A, Valentino ML, Liguori R, Barboni P, Martinuzzi A, Tonon C, Lodi R, Torroni A, Carelli V, Ghelli AM.   +15 more
europepmc   +1 more source

Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women

British Journal of Clinical Pharmacology, EarlyView.
Aims While pregnancy‐related changes in phase I enzyme activity are well‐documented, less is known about the impact on phase II enzymes. This study aimed to test the hypothesis that changes in the pharmacokinetics (PK) of uridine 5′‐diphosphoglucuronosyltransferase (UGT) substrates during pregnancy result from altered enzyme expression or activity ...
William Saffaf, Ymke van der Velde, Paul R. V. Malik, Jelmer R. Prins, Sanne J. Gordijn, Daan J. Touw, Paola Mian   +6 more
wiley   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

The cytochrome b carboxyl-terminal region is necessary for mitochondrial Complex III assembly

, 2022
Flores-Mireles D, Camacho-Villasana Y, Lutikurti M, García-Guerrero AE, Lozano-Rosas G, Chagoya V, Gutiérrez-Cirlos EB, Brandt U, Cabrera-Orefice A, Pérez-Martínez X.   +9 more
europepmc   +1 more source

Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity

British Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 1A2 (CYP1A2) exhibits substantial interindividual variability, necessitating appropriate phenotyping strategies for personalized pharmacotherapy. This study evaluated endogenous melatonin partial metabolic clearance (CLm(MEL)), calculated from urinary 6‐hydroxymelatonin (6‐O‐MEL) excretion and plasma melatonin (MEL) exposure, as a ...
Akitomo Yokokawa, Hayato Shimazaki, Shunji Igarashi, Yoshiki Tagawa, Naoki Hisada, Hiromi Shibasaki   +5 more
wiley   +1 more source

The Thienopyrimidinone Gamhépathiopine Targets the Q_O Site of <i>Plasmodium falciparum</i> Cytochrome <i>b</i>. [PDF]

ACS Infect Dis
Wiedemar N, Milne R, Carvalho S, Patterson S, Bodkin M, Masurier N, Lisowski V, Primas N, Verhaeghe P, Sloan GM, Wyllie S.   +10 more
europepmc   +1 more source

Optimal dosing for vascular anomalies paediatric patients with population pharmacokinetic model of sirolimus

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Sirolimus is currently used off‐label for paediatric patients with vascular anomalies. However, the optimal dosage regimen for paediatric patients remains controversial. This study aimed to determine the optimal dosing regimen of sirolimus in these patients using a population pharmacokinetic (PK) model.
Seongmee Jeong, Jungryul Kim, Woojin Jung, Jiyeon Jeon, Hyeongjun Jo, Kyoung‐Bin Ryu, Ja‐Young Hong, Kwan Soo Kim, Seongjun Yang, Hee Young Ju, Hwi‐yeol Yun, Jung‐woo Chae, Keon Hee Yoo, Soyoung Lee   +13 more
wiley   +1 more source

Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis

British Journal of Clinical Pharmacology, EarlyView.
Aim The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor–tezacaftor–ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population.
Paulette Magnas, Naim Bouazza, Frantz Foissac, Saïk Urien, Léo Froelicher‐Bournaud, Gabrielle Lui, Victoria Guillemart, Nicolas Carlier, Jennifer Da Silva, Johanna Fesenbeckh, Reem Kanaan, Isabelle Honoré, Clémence Martin, Jean‐Marc Treluyer, Vassilis Tsatsaris, Pierre‐Régis Burgel, Sihem Benaboud   +16 more
wiley   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source